DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the first quarter of 2024.
- DiaMedica Therapeutics reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -16 cents.
- The company did not report any revenue for the quarter.